<?xml version='1.0' encoding='utf-8'?>
<document id="26684498"><sentence text="Contribution of Major Metabolites toward Complex Drug-Drug Interactions of Deleobuvir: In Vitro Predictions and In Vivo Outcomes." /><sentence text="The drug-drug interaction (DDI) potential of deleobuvir, an hepatitis C virus (HCV) polymerase inhibitor, and its two major metabolites, CD 6168 (formed via reduction by gut bacteria) and deleobuvir-acyl glucuronide (AG), was assessed in vitro"><entity charOffset="188-215" id="DDI-PubMed.26684498.s2.e0" text="deleobuvir-acyl glucuronide" /><entity charOffset="217-219" id="DDI-PubMed.26684498.s2.e1" text="AG" /><pair ddi="false" e1="DDI-PubMed.26684498.s2.e0" e2="DDI-PubMed.26684498.s2.e0" /><pair ddi="false" e1="DDI-PubMed.26684498.s2.e0" e2="DDI-PubMed.26684498.s2.e1" /></sentence><sentence text=" Area-under-the-curve (AUC) ratios (AUCi/AUC) were predicted using a static model and compared with actual AUC ratios for probe substrates in a P450 cocktail of caffeine (CYP1A2), tolbutamide (CYP2C9), and midazolam (CYP3A4), administered before and after 8 days of deleobuvir administration to HCV-infected patients"><entity charOffset="161-169" id="DDI-PubMed.26684498.s3.e0" text="caffeine" /><entity charOffset="180-191" id="DDI-PubMed.26684498.s3.e1" text="tolbutamide" /><entity charOffset="193-199" id="DDI-PubMed.26684498.s3.e2" text="CYP2C9" /><entity charOffset="206-215" id="DDI-PubMed.26684498.s3.e3" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.26684498.s3.e0" e2="DDI-PubMed.26684498.s3.e0" /><pair ddi="false" e1="DDI-PubMed.26684498.s3.e0" e2="DDI-PubMed.26684498.s3.e1" /><pair ddi="false" e1="DDI-PubMed.26684498.s3.e0" e2="DDI-PubMed.26684498.s3.e2" /><pair ddi="false" e1="DDI-PubMed.26684498.s3.e0" e2="DDI-PubMed.26684498.s3.e3" /><pair ddi="false" e1="DDI-PubMed.26684498.s3.e1" e2="DDI-PubMed.26684498.s3.e1" /><pair ddi="false" e1="DDI-PubMed.26684498.s3.e1" e2="DDI-PubMed.26684498.s3.e2" /><pair ddi="false" e1="DDI-PubMed.26684498.s3.e1" e2="DDI-PubMed.26684498.s3.e3" /><pair ddi="false" e1="DDI-PubMed.26684498.s3.e2" e2="DDI-PubMed.26684498.s3.e2" /><pair ddi="false" e1="DDI-PubMed.26684498.s3.e2" e2="DDI-PubMed.26684498.s3.e3" /></sentence><sentence text=" In vitro studies assessed inhibition, inactivation and induction of P450s" /><sentence text=" Induction was assessed in a short-incubation (10 hours) hepatocyte assay, validated using positive controls, to circumvent cytotoxicity seen with deleobuvir and its metabolites"><entity charOffset="147-157" id="DDI-PubMed.26684498.s5.e0" text="deleobuvir" /></sentence><sentence text=" Overall, P450 isoforms were differentially affected by deleobuvir and its two metabolites" /><sentence text=" Of note was more potent CYP2C8 inactivation by deleobuvir-AG than deleobuvir and P450 induction by CD 6168 but not by deleobuvir"><entity charOffset="59-68" id="DDI-PubMed.26684498.s7.e0" text="AG" /></sentence><sentence text=" The predicted net AUC ratios for probe substrates were 2" /><sentence text="92 (CYP1A2), 0" /><sentence text="45 (CYP2C9), and 0" /><sentence text="97 (CYP3A4) compared with clinically observed ratios of 1" /><sentence text="64 (CYP1A2), 0" /><sentence text="86 (CYP2C9), and 1" /><sentence text="23 (CYP3A4)" /><sentence text=" Predictions of DDI using deleobuvir alone would have significantly over-predicted the DDI potential for CYP3A4 inhibition (AUC ratio of 6" /><sentence text="15)" /><sentence text=" Including metabolite data brought the predicted net effect close to the observed DDI" /><sentence text=" However, the static model over-predicted the induction of CYP2C9 and inhibition/inactivation of CYP1A2" /><sentence text=" This multiple-perpetrator DDI scenario highlights the application of the static model for predicting complex DDI for CYP3A4 and exemplifies the importance of including key metabolites in an overall DDI assessment" /><sentence text=" " /></document>